Agilon Health price target lowered to $23 from $27 at Truist

Truist lowered the firm’s price target on Agilon Health to $23 from $27 but keeps a Buy rating on the shares. The stock is now down 25% since reporting results last week, with investor concerns revolving around the company’s ability to appropriately capture medical utilization trends given the risk to 2024 and long-term expectations, the analyst tells investors in a research note. Truist adds however that it continues to believe that Agilon has shown an ability to inflect medical margins, which supports its long-term view on shares.